Long Term Defibrinogenation Therapy for Sudden Deafness

Abstract

The etiology of sudden deafness is unknown, but ischemia of the inner ear is believed to be one of the major causes of sudden deafness. We administered Batroxobin for over 28 days at dosages of over 150 B. U., to 10 patients with sudden deafness. After this treatment, the hearing level improved significantly in 9 out of the 10 patients. The less satisfactory result in the one patient could be attributed to a failure in the control of his plasma fibrinogen levels. We believe that this therapy can be very effective, provided that the side effects of this therapy are well understood by both patients and the medical staff.
The treatment of sudden deafness with Batroxobin is discussed in this report, based on our experiences with long term defibrinogenation therapy.